Google
SLXN — BIOMOTION SCIENCES ORDINARY SHARES (Healthcare >> Biotechnology)
SLXN FAQ
What is SLXN's ROE?
BIOMOTION SCIENCES ORDINARY SHARES reports a Return on Equity (ROE) of -4,436.43%.
What is SLXN's dividend yield?
BIOMOTION SCIENCES ORDINARY SHARES offers a dividend yield of 0.00%.
What is SLXN's Deepscope Quality Score?
Deepscope rates SLXN's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SLXN?
Deepscope's AI Timing Score for SLXN is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SLXN belong to?
BIOMOTION SCIENCES ORDINARY SHARES is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.06
Price
-1.11
(-26.62%)
Day Change
|
|
|---|
SLXN, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.06 |
| PBV / Sector |
6.00 / 4.79
|
| Earning Per Share | -22.61 |
| PE / Sector |
N/A / 17.89
|
| PEG or PE/Growth / Sector |
N/A / 0.56
|
| Average 1M Daily Value |
9.34 M
|
| Average 1W Daily Value |
0.48 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-11 09:54:46 |
| Symbol | SLXN |
| Name | BIOMOTION SCIENCES ORDINARY SHARES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 0.42 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1.75 / 8,963.32 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: The Goldyne Savad Inst. of Gene Therapy, Jerusalem, Israel, 9112001
Phone: 972 2 674 3430
Website: https://silexion.com
Sector: Healthcare >> Biotechnology
Description: Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
